激素受体阳性-话题@MedSci

#激素受体阳性#

54篇内容 | 2684人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1980843, encodeId=17ee198084329, content=<a href='/topic/show?id=aaf6668192d' target=_blank style='color:#2F92EE;'>#激素受体阳性#</a>, objectTitle=NEJM：早期雌激素受体阳性乳腺癌患者内分泌治疗后5-20年复发风险及影响因素研究, objectType=article, longId=119387, objectId=842511938e6a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=842511938e6a, replyNumber=0, likeNumber=79, createdTime=2018-07-19, rootId=0, userName=mjldent, userId=5662228, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=842511938e6a, moduleTitle=NEJM：早期雌激素受体阳性乳腺癌患者内分泌治疗后5-20年复发风险及影响因素研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=842511938e6a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1980846, encodeId=237e198084610, content=<a href='/topic/show?id=aaf6668192d' target=_blank style='color:#2F92EE;'>#激素受体阳性#</a>, objectTitle=Oncogene：USP14调节的雄激素受体去泛素化的抑制能够促使雄激素受体阳性乳腺癌细胞的生长停滞和凋亡诱导, objectType=article, longId=129021, objectId=108c1290212c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=108c1290212c, replyNumber=0, likeNumber=95, createdTime=2018-11-29, rootId=0, userName=mjldent, userId=5662228, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=108c1290212c, moduleTitle=Oncogene：USP14调节的雄激素受体去泛素化的抑制能够促使雄激素受体阳性乳腺癌细胞的生长停滞和凋亡诱导, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=108c1290212c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1980844, encodeId=9a7a19808448c, content=<a href='/topic/show?id=aaf6668192d' target=_blank style='color:#2F92EE;'>#激素受体阳性#</a>, objectTitle=Lancet oncol：Buparlisib联合氟维司群用于内分泌疗法和mTOR抑制剂治疗失败的雌激素受体阳性、HER2阴性的晚期乳腺癌患者的效果和安全性。, objectType=article, longId=122620, objectId=45fb122620ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=45fb122620ba, replyNumber=0, likeNumber=110, createdTime=2018-10-02, rootId=0, userName=mjldent, userId=5662228, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=45fb122620ba, moduleTitle=Lancet oncol：Buparlisib联合氟维司群用于内分泌疗法和mTOR抑制剂治疗失败的雌激素受体阳性、HER2阴性的晚期乳腺癌患者的效果和安全性。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=45fb122620ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1980842, encodeId=0c4e198084283, content=<a href='/topic/show?id=aaf6668192d' target=_blank style='color:#2F92EE;'>#激素受体阳性#</a>, objectTitle=张敬杰教授：绝经后激素受体阳性乳腺癌患者心血管风险的有效管理, objectType=article, longId=117232, objectId=5d1011e232cf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5d1011e232cf, replyNumber=0, likeNumber=90, createdTime=2018-01-02, rootId=0, userName=mjldent, userId=5662228, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5d1011e232cf, moduleTitle=张敬杰教授：绝经后激素受体阳性乳腺癌患者心血管风险的有效管理, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5d1011e232cf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1980838, encodeId=625b1980838e8, content=<a href='/topic/show?id=aaf6668192d' target=_blank style='color:#2F92EE;'>#激素受体阳性#</a>, objectTitle=Lancet：对于雌激素受体阳性的晚期乳腺癌患者氟维司群疗效比阿那曲唑更好, objectType=article, longId=83273, objectId=a635832e3b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a635832e3b6, replyNumber=0, likeNumber=73, createdTime=2017-06-28, rootId=0, userName=mjldent, userId=5662228, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a635832e3b6, moduleTitle=Lancet：对于雌激素受体阳性的晚期乳腺癌患者氟维司群疗效比阿那曲唑更好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a635832e3b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1980839, encodeId=01371980839e6, content=<a href='/topic/show?id=aaf6668192d' target=_blank style='color:#2F92EE;'>#激素受体阳性#</a>, objectTitle=引发雌激素受体阳性或阴性乳腺癌的风险因素是否扮演着相同的角色？, objectType=article, longId=87775, objectId=93e38e7752a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=93e38e7752a, replyNumber=0, likeNumber=76, createdTime=2017-08-30, rootId=0, userName=mjldent, userId=5662228, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=93e38e7752a, moduleTitle=引发雌激素受体阳性或阴性乳腺癌的风险因素是否扮演着相同的角色？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=93e38e7752a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1980837, encodeId=7fc0198083e60, content=<a href='/topic/show?id=aaf6668192d' target=_blank style='color:#2F92EE;'>#激素受体阳性#</a>, objectTitle=ESMO 2016：来曲唑+Ribociclib可延长激素受体阳性、HER-2阴性晚期乳腺癌患者的PFS（MONALEESA-2试验）, objectType=article, longId=79630, objectId=1d17e9630e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1d17e9630e6, replyNumber=0, likeNumber=101, createdTime=2017-07-01, rootId=0, userName=mjldent, userId=5662228, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1d17e9630e6, moduleTitle=ESMO 2016：来曲唑+Ribociclib可延长激素受体阳性、HER-2阴性晚期乳腺癌患者的PFS（MONALEESA-2试验）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1d17e9630e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1980836, encodeId=068e1980836fb, content=<a href='/topic/show?id=aaf6668192d' target=_blank style='color:#2F92EE;'>#激素受体阳性#</a>, objectTitle=Breast Cancer Res：福音！他汀类药物或可有效治疗雌激素受体阳性的乳腺癌女性, objectType=article, longId=69839, objectId=015a69839d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=015a69839d9, replyNumber=0, likeNumber=110, createdTime=2016-08-10, rootId=0, userName=mjldent, userId=5662228, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=015a69839d9, moduleTitle=Breast Cancer Res：福音！他汀类药物或可有效治疗雌激素受体阳性的乳腺癌女性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=015a69839d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1980834, encodeId=c47d1980834a5, content=<a href='/topic/show?id=aaf6668192d' target=_blank style='color:#2F92EE;'>#激素受体阳性#</a>, objectTitle=NEJM:palbociclib对激素受体阳性的晚期乳腺癌患者的疗效, objectType=article, longId=51550, objectId=8299515501e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8299515501e, replyNumber=0, likeNumber=75, createdTime=2016-02-12, rootId=0, userName=mjldent, userId=5662228, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8299515501e, moduleTitle=NEJM:palbociclib对激素受体阳性的晚期乳腺癌患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8299515501e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1980835, encodeId=151d198083591, content=<a href='/topic/show?id=aaf6668192d' target=_blank style='color:#2F92EE;'>#激素受体阳性#</a>, objectTitle=招募患者：西达本胺联合依西美坦治疗激素受体阳性晚期乳腺癌的III期临床试验, objectType=article, longId=56014, objectId=262d56014f0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=262d56014f0, replyNumber=0, likeNumber=73, createdTime=2016-06-08, rootId=0, userName=mjldent, userId=5662228, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=262d56014f0, moduleTitle=招募患者：西达本胺联合依西美坦治疗激素受体阳性晚期乳腺癌的III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=262d56014f0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1980833, encodeId=f303198083393, content=<a href='/topic/show?id=aaf6668192d' target=_blank style='color:#2F92EE;'>#激素受体阳性#</a>, objectTitle=BMC cancer：单一激素受体阳性预后与三阴乳腺癌相当？, objectType=article, longId=48405, objectId=c4184840541, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c4184840541, replyNumber=0, likeNumber=74, createdTime=2015-06-07, rootId=0, userName=mjldent, userId=5662228, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c4184840541, moduleTitle=BMC cancer：单一激素受体阳性预后与三阴乳腺癌相当？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c4184840541)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1980832, encodeId=c1621980832b0, content=<a href='/topic/show?id=aaf6668192d' target=_blank style='color:#2F92EE;'>#激素受体阳性#</a>, objectTitle=雌激素受体阳性乳腺癌的新治疗方法, objectType=article, longId=44180, objectId=7af44418035, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7af44418035, replyNumber=0, likeNumber=101, createdTime=2015-08-31, rootId=0, userName=mjldent, userId=5662228, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7af44418035, moduleTitle=雌激素受体阳性乳腺癌的新治疗方法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7af44418035)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1980831, encodeId=497d19808314c, content=<a href='/topic/show?id=aaf6668192d' target=_blank style='color:#2F92EE;'>#激素受体阳性#</a>, objectTitle=CSCO 2014：绝经后激素受体阳性乳腺癌高危人群风险控制, objectType=article, longId=40451, objectId=7970404514f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7970404514f, replyNumber=0, likeNumber=88, createdTime=2015-03-20, rootId=0, userName=mjldent, userId=5662228, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7970404514f, moduleTitle=CSCO 2014：绝经后激素受体阳性乳腺癌高危人群风险控制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7970404514f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1980830, encodeId=df1d198083046, content=<a href='/topic/show?id=aaf6668192d' target=_blank style='color:#2F92EE;'>#激素受体阳性#</a>, objectTitle=Lancet：持续三苯氧胺治疗10年能降低雌激素受体阳性的乳腺癌患者的复发率和死亡率, objectType=article, longId=18294, objectId=ae70182943f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ae70182943f, replyNumber=0, likeNumber=76, createdTime=2013-05-13, rootId=0, userName=mjldent, userId=5662228, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ae70182943f, moduleTitle=Lancet：持续三苯氧胺治疗10年能降低雌激素受体阳性的乳腺癌患者的复发率和死亡率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ae70182943f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1980829, encodeId=f6b81980829cf, content=<a href='/topic/show?id=aaf6668192d' target=_blank style='color:#2F92EE;'>#激素受体阳性#</a>, objectTitle=NEJM：依维莫司用于绝经后的激素受体阳性的晚期乳腺癌, objectType=article, longId=4156, objectId=55364156f1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=55364156f1, replyNumber=0, likeNumber=83, createdTime=2012-11-19, rootId=0, userName=mjldent, userId=5662228, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=55364156f1, moduleTitle=NEJM：依维莫司用于绝经后的激素受体阳性的晚期乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=55364156f1)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

激素受体阳性

2020-05-29

mjldent

#激素受体阳性#

NEJM：早期雌激素受体阳性乳腺癌患者内分泌治疗后5-20年复发风险及影响因素研究

2018-07-19

mjldent

#激素受体阳性#

Oncogene：USP14调节的雄激素受体去泛素化的抑制能够促使雄激素受体阳性乳腺癌细胞的生长停滞和凋亡诱导

2018-11-29

mjldent

#激素受体阳性#

Lancet oncol：Buparlisib联合氟维司群用于内分泌疗法和mTOR抑制剂治疗失败的雌激素受体阳性、HER2阴性的晚期乳腺癌患者的效果和安全性。

2018-10-02

mjldent

#激素受体阳性#

张敬杰教授：绝经后激素受体阳性乳腺癌患者心血管风险的有效管理

2018-01-02

mjldent

#激素受体阳性#

Lancet：对于雌激素受体阳性的晚期乳腺癌患者氟维司群疗效比阿那曲唑更好

2017-06-28

mjldent

#激素受体阳性#

引发雌激素受体阳性或阴性乳腺癌的风险因素是否扮演着相同的角色？

2017-08-30

mjldent

#激素受体阳性#

ESMO 2016：来曲唑+Ribociclib可延长激素受体阳性、HER-2阴性晚期乳腺癌患者的PFS（MONALEESA-2试验）

2017-07-01

mjldent

#激素受体阳性#

Breast Cancer Res：福音！他汀类药物或可有效治疗雌激素受体阳性的乳腺癌女性

2016-08-10

mjldent

#激素受体阳性#

NEJM:palbociclib对激素受体阳性的晚期乳腺癌患者的疗效

2016-02-12

mjldent

#激素受体阳性#

招募患者：西达本胺联合依西美坦治疗激素受体阳性晚期乳腺癌的III期临床试验

2016-06-08

mjldent

#激素受体阳性#

BMC cancer：单一激素受体阳性预后与三阴乳腺癌相当？

2015-06-07

mjldent

#激素受体阳性#

雌激素受体阳性乳腺癌的新治疗方法

2015-08-31

mjldent

#激素受体阳性#

CSCO 2014：绝经后激素受体阳性乳腺癌高危人群风险控制

2015-03-20

mjldent

#激素受体阳性#

Lancet：持续三苯氧胺治疗10年能降低雌激素受体阳性的乳腺癌患者的复发率和死亡率

2013-05-13

mjldent

#激素受体阳性#

NEJM：依维莫司用于绝经后的激素受体阳性的晚期乳腺癌

2012-11-19